13 recruiting, 12 active not recruiting, 3 not yet recruiting, 1 completed. 30 Phase 2, 5 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 30 | Recruiting 13, Active not recruiting 12, Not yet recruiting 3, Completed 1, Suspended 1 |
| Phase 1 | 5 | Active not recruiting 3, Recruiting 1, Suspended 1 |
| Phase 3 | 2 | Not yet recruiting 2 |
Follow Sb27: new trials by email Literature Review of Sb27 trials Research Report on Sb27
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 336 | 2027-01-11 | 2026-08-14 |
| Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment Biospecimen Collection, Brentuximab Vedotin, Computed Tomography - Classic Hodgkin Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 23 | 2027-01-01 | 2026-11-12 |
| Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma 3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection - Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 374 | 2026-12-04 | 2026-07-08 |
| CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery to Improve Treatment of Melanoma Brain Metastases Emavusertib, Pembrolizumab, Stereotactic Radiosurgery - Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma | Phase 1 / Phase 2 | Suspended | Mayo Clinic | 23 | 2026-11-30 | 2026-10-20 |
| Proton Spatially Fractionated Radiotherapy or Photon Stereotactic Body Radiotherapy in Combination With Pembrolizumab Before Surgery for the Treatment of Locally Advanced and Radiation-Naive Locoregionally Recurrent Oral Cavity Cancer, OSPRI Trial Biopsy Procedure, Biospecimen Collection, Computed Tomography - Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 30 | 2026-11-04 | 2026-11-06 |
| Induction Chemoimmunotherapy to Prevent Laryngectomy in Advanced Laryngeal Cancer and Hypopharyngeal Cancer Biospecimen Collection, Carboplatin, Chemotherapy - Advanced Laryngeal Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Mayo Clinic | 50 | 2026-11-01 | 2026-11-09 |
| Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer Quemliclustat, Biospecimen Collection, Computed Tomography - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 27 | 2026-10-20 | 2026-10-22 |
| GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma Biospecimen Collection, Bispecific CD80-lgG4Fc-IL-2v Fusion Protein GI-102, Computed Tomography - Glioblastoma, IDH-Wildtype, Progressive Astrocytoma, IDH-Mutant, Grade 4 | Phase 2 | Recruiting | Mayo Clinic | 36 | 2026-08-03 | 2026-10-30 |
| Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery Biospecimen Collection, Clostridium butyricum CBM588 Strain, Computed Tomography - Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma | Phase 2 | Recruiting | City of Hope Medical Center | 62 | 2026-07-08 | 2026-10-19 |
| GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer Anti-CFH Monoclonal Antibody GT103, Biopsy Procedure, Biospecimen Collection - Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 28 | 2026-04-01 | 2026-08-19 |
| Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial Biospecimen Collection, Computed Tomography, Cystoscopy - Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 111 | 2025-11-25 | 2026-11-03 |
| Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial Biospecimen Collection, Hormone Therapy, Pembrolizumab - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 120 | 2025-10-09 | 2026-11-03 |
| Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC Biospecimen Collection, Breast Biopsy Procedure, Carboplatin - Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 2 | Recruiting | Vandana Abramson | 51 | 2025-09-09 | 2025-10-30 |
| Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers Best Practice, Biospecimen Collection, Central Venous Cannula Insertion - Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 70 | 2025-08-01 | 2026-05-08 |
| Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial Biospecimen Collection, Cisplatin, Computed Tomography - Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 160 | 2025-06-03 | 2026-11-09 |
| Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial Avelumab, Axitinib, Biospecimen Collection - Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8 | Phase 2 | Recruiting | NRG Oncology | 240 | 2023-02-01 | 2026-10-23 |
| Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck Biopsy Procedure, Biospecimen Collection, Computed Tomography - Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 52 | 2022-07-26 | 2026-11-12 |
| A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 60 | 2021-10-15 | 2026-11-12 |
| Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma Carboplatin, Cisplatin, Computed Tomography - Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 188 | 2021-04-27 | 2026-11-12 |
| Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer Berzosertib, Biospecimen Collection, Carboplatin - Lung Non-Small Cell Squamous Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 12 | 2021-04-14 | 2026-11-13 |
Showing 20 of 30. Sign in to see all of them.
Urinary Bladder Neoplasms (6) · Squamous Cell Carcinoma of Head and Neck (4) · Melanoma (3) · Carcinoma, Renal Cell (2) · Laryngeal Neoplasms (2) · Leukemia, Myeloid, Acute (2) · Lung Neoplasms (2) · Ureteral Neoplasms (2) · Astrocytoma (1) · Brain Neoplasms (1) · Carcinoma (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Cholangiocarcinoma (1)
National Cancer Institute (NCI) (17) · Mayo Clinic (5) · City of Hope Medical Center (2) · ECOG-ACRIN Cancer Research Group (1) · Fred Hutchinson Cancer Center (1) · M.D. Anderson Cancer Center (1) · NRG Oncology (1) · Roswell Park Cancer Institute (1) · Vandana Abramson (1)
United States (28) · Canada (4) · Australia (1) · Guam (1) · Ireland (1) · Puerto Rico (1)
Amer M Zeidan (2) · Aaron S Mansfield (1) · Ahmad Tarhini (1) · Bently Doonan, MD, MS (1) · Brian C Baumann (1) · Dan P Zandberg (1) · Daniel K. Ebner, MD, MPH (1) · Deirdre J Cohen (1) · Edwin H Yau (1) · Jacob J. Orme, MD, PhD (1) · Jacob S Thomas (1) · Jason J Luke (1) · Jessica M. Wilson, MD, PhD (1) · Jian L Campian, MD, PhD (1) · Kari L Kendra (1)
PMID 36648215, PMID 36856617, PMID 37104746, PMID 40811146, PMID 40813711, PMID 41206673, PMID 41611998
U10CA180888 (5), U10CA180820 (4), P30CA033572 (2), U10CA180821 (2), U10CA180868 (2), UM1CA186689 (2), P30CA016672 (1), P30CA060553 (1), P30CA068485 (1), UM1CA186686 (1), UM1CA186690 (1), UM1CA186709 (1), UM1CA186717 (1)